Evidence map›Paper›PMID 38150135›Full record

ArticleBreast cancer (Tokyo, Japan)2024

The influence of chronic renal insufficiency on multi-therapeutic modalities for breast cancer: a single-center experience.

Yi-Wen Hong, I-Ming Kuo, Wen-Ling Kuo, Chi-Chang Yu, Shih-Che Shen, Hsiu-Pei Tsai, Chia-Hui Chu, Hui-Yu Ho, Yung-Feng Lo, Shin-Cheh Chen and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 66% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 0 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Yi-Wen HongDivision of General Surgery, Department of Surgery, New Taipei Municipal TuCheng Hospital, No. 6, Sec. 2, Jincheng Rd., Tucheng Dist., New Taipei City, 236, Taiwan.
I-Ming KuoDivision of General Surgery, Department of Surgery, New Taipei Municipal TuCheng Hospital, No. 6, Sec. 2, Jincheng Rd., Tucheng Dist., New Taipei City, 236, Taiwan. ming.aska@msa.hinet.net.ORCID http://orcid.org/0000-0002-9993-7498
Wen-Ling KuoDivision of General Surgery, Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, No. 5, Fuxing St., Guishan Dist., Taoyuan City, 333, Taiwan.
Chi-Chang YuDivision of General Surgery, Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, No. 5, Fuxing St., Guishan Dist., Taoyuan City, 333, Taiwan.
Shih-Che ShenDivision of General Surgery, Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, No. 5, Fuxing St., Guishan Dist., Taoyuan City, 333, Taiwan.
Hsiu-Pei TsaiDivision of General Surgery, Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, No. 5, Fuxing St., Guishan Dist., Taoyuan City, 333, Taiwan.
Chia-Hui ChuDivision of General Surgery, Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, No. 5, Fuxing St., Guishan Dist., Taoyuan City, 333, Taiwan.
Hui-Yu HoDivision of General Surgery, Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, No. 5, Fuxing St., Guishan Dist., Taoyuan City, 333, Taiwan.
Yung-Feng LoDivision of General Surgery, Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, No. 5, Fuxing St., Guishan Dist., Taoyuan City, 333, Taiwan.
Shin-Cheh ChenDivision of General Surgery, Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, No. 5, Fuxing St., Guishan Dist., Taoyuan City, 333, Taiwan.
Yung-Chang LinDivision of Medical Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan.
Chih-Ying ChienDivision of General Surgery, Department of Surgery, Chang Gung Memorial Hospital, Keelung, Taiwan.
Hsu-Huan ChouDivision of General Surgery, Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, No. 5, Fuxing St., Guishan Dist., Taoyuan City, 333, Taiwan. b9002009@cgmh.org.tw.
Chang Gung University · TWChang Gung Memorial Hospital · TWKeelung Chang Gung Memorial Hospital · TWTaipei Municipal YangMing Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDue to the presence of other comorbidities and multi-therapeutic modalities in breast cancer, renally cleared chemotherapeutic regimens may cause nephrotoxicity. The aim of this retrospective study is to compare the chemotherapy types and outcomes in breast cancer patients with or without chronic renal disease. PATIENTS AND

methodsWe retrospectively enrolled 62 female patients with breast cancer and underlying late stages (stage 3b, 4, and 5) of chronic kidney disease (CKD) treated from 2000 to 2017. They were propensity score-matched 1:1 with patients in our database with breast cancer and normal renal function (total n = 124).

resultsThe main subtype of breast cancer was luminal A and relatively few patients with renal impairment received chemotherapy and anti-Her-2 treatment. The breast cancer patients with late-stage CKD had a slightly higher recurrent rate, especially at the locally advanced stage. The 5-year overall survival was 90.1 and 71.2% for patients without and with late-stage CKD, but the breast cancer-related mortality rate was 88.9 and 24.1%, respectively. In multivariate analyses, dose-reduced chemotherapy was an independent negative predictor of 5-year recurrence-free survival and late-stage CKD was associated with lower 5-year overall survival rate.

conclusionsBreast cancer patients with late-stage CKD may receive insufficient therapeutic modalities. Although the recurrence-free survival rate did not differ significantly by the status of CKD, patients with breast cancer and late-stage CKD had shorter overall survival time but a lower breast cancer-related mortality rate, indicated that the mortality was related to underlying disease.

Indexed as

Breast NeoplasmsRenal Insufficiency, ChronicFemaleGlomerular Filtration RateHumansRetrospective StudiesSurvival RateBreast cancerChemotherapyChronic kidney diseaseEnd-stage renal diseasePrognosisPropensity score matching

Identifiers

PMID38150135
PMCPMC10901917
OpenAlexW4390268421

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.